Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
MIGDAL HA'EMEQ, Israel, July 26, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) (“Enzymotec” or the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Wednesday, August 16, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, August 16, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #54908799 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/fsb2hqfy, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Investor Relations Contact (U.S.) The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
